Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity

2020 ◽  
Vol 98 (8) ◽  
Author(s):  
Yong Cheng ◽  
Xuemei Zhu ◽  
Dandan Linghu ◽  
Jianhong Liang
Keyword(s):  
Retinopathy Of Prematurity ◽  
Ranibizumab Treatment

SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY

Retina ◽  
2017 ◽  
Vol 37 (4) ◽  
pp. 694-701 ◽  
Author(s):  
Wei-Chi Wu ◽  
Chia-Pang Shih ◽  
Reyin Lien ◽  
Nan-Kai Wang ◽  
Yen-Po Chen ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Retinopathy Of Prematurity ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Ranibizumab Treatment

scholarly journals Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Qiujing Huang ◽  
Qi Zhang ◽  
Yu Xu ◽  
Xunda Ji ◽  
Ping Fei ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Retinopathy Of Prematurity ◽  
Vitreous Hemorrhage ◽  
High Rate ◽  
Intravitreal Ranibizumab ◽  
Outcome Group ◽  
Significant Difference ◽  
Type 1 Rop ◽  
Ranibizumab Treatment

Purpose. To present cases with retinopathy of prematurity (ROP), who were treated with intravitreal injection of ranibizumab (IVR) and had unpredictable asymmetric outcomes. Methods. A retrospective review was performed in infants with type 1 ROP and had bilateral IVR (0.25 mg/0.025 mL) as initial treatment. Patients were classified into the asymmetric outcome group and the symmetric outcome group. Results. Eighty-four patients (168 eyes) were included. There were 18 eyes of 9 patients (10.7%) in the asymmetric outcome group and 150 eyes of 75 patients (89.3%) in the symmetric outcome group. In the symmetric outcome group, 86 eyes (57.3%) had ROP regression, 60 eyes (40%) had reactivation requiring laser treatment, and 4 eyes (2.7%) progressed to retinal detachment requiring vitrectomy. In the asymmetric outcome group, one of the eyes of the 9 patients had ROP regression with/without reactivation after IVR, while the contralateral eyes had negative response, including remarkable posterior fibrosis, partial or total retinal detachment, and vitreous hemorrhage. There was statistically significant difference between the birth weight of the two groups. Conclusion. Contralateral eyes with ROP can take a different clinical course after ranibizumab treatment. High rate of reactivation after IVR is another concern that ophthalmologists should pay attention to.

Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment

2016 ◽  
Vol 47 (12) ◽  
pp. 1095-1105 ◽  
Author(s):  
Tsengelmaa Chuluunbat ◽  
R.V. Paul Chan ◽  
Nan-Kai Wang ◽  
Reyin Lien ◽  
Yen-Po Chen ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Intravitreal Ranibizumab ◽  
Ranibizumab Treatment

scholarly journals Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Qinrui Hu ◽  
Yujing Bai ◽  
Xiaoli Chen ◽  
Lvzhen Huang ◽  
Yi Chen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Multivariate Analysis ◽  
Retrospective Study ◽  
Intravitreal Injection ◽  
Retinopathy Of Prematurity ◽  
Initial Treatment ◽  
Univariate Analysis ◽  
Outcome Data ◽  
Zone Ii ◽  
Ranibizumab Treatment

Objective. To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment.Methods. This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases. Infants who developed Zone II Stage 3 ROP with plus disease and underwent initial intravitreal injection of ranibizumab (IVR) were recruited. Patients were divided into 2 groups based on the outcome after initial ranibizumab treatment: recurrence of ROP or favorable outcome. Data was collected and analyzed by SPSS 16.0.Results. Forty-two patients were included, and 80 eyes with Zone II Stage 3+ were subjected to IVR treatment. Eleven of 42 patients (26.2%, 18 eyes) had a recurrence of ROP after the initial treatment. On univariate analysis, preretinal hemorrhage before treatment was significantly different between the two groups (P=0.000). Multivariate analysis found that preretinal hemorrhage before treatment was the only factor associated with the recurrence of ROP in our study (P=0.004).Conclusions. The recurrence rate of ROP in Zone II Stage 3+ after initial ranibizumab treatment was notable and preretinal hemorrhage before treatment was associated with the recurrence of ROP in our study.

Fibrovascular proliferation of retinopathy of prematurity in zone II after initial ranibizumab treatment

2018 ◽  
Vol 2 ◽  
pp. 48-48
Author(s):  
Qinrui Hu ◽  
Yujing Bai ◽  
Xiaoli Chen ◽  
Huika Xia ◽  
Lvzhen Huang ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Fibrovascular Proliferation ◽  
Zone Ii ◽  
Ranibizumab Treatment

REACTIVATION OF RETINOPATHY OF PREMATURITY AFTER RANIBIZUMAB TREATMENT

Retina ◽  
2015 ◽  
Vol 35 (4) ◽  
pp. 675-680 ◽  
Author(s):  
Ryan K. Wong ◽  
Sasha Hubschman ◽  
Irena Tsui
Keyword(s):  
Retinopathy Of Prematurity ◽  
Ranibizumab Treatment
Sign in / Sign up

Export Citation Format

Share Document